Meet our Board of Directors
Antibe’s Board of Directors comprises experts in corporate governance, growth financing, financial control, risk management, pharmacology, pharmaceutical development and large pharma transactions. All Directors are investors in the Company. Learn about Antibe’s corporate governance practices.
Vice Chairman Mastercard Incorporated, USA
MBA Schulich School of Business, York University, Canada
Walt is the founder of Mastercard’s Center for Inclusive Growth, and has chaired the Centre for Social Impact at Queen’s University, and Convergence Finance. He has been a board member of Save the Children Canada, Big Brothers Big Sisters of Canada, the Royal Conservatory of Music, and the Sunnybrook Hospital Foundation.
“Better medicines for pain promise a better world for billions of people.”
Emeritus Professor, Pharmacology William Harvey Research Institute, Queen Mary University, UK
PhD Pharmacology University of London, UK
Rod is a recipient of several awards, including the William Withering Prize of the Royal College of Physicians, the Wellcome Gold Medal of the British Pharmacological Society, and the Lifetime Achievement Award of the International Association of Inflammation Societies.
“I believe that Antibe has made a landmark advance towards a safer treatment for inflammation.”
VP Business Development Knight Therapeutics, Canada
MBA University of Ottawa, Canada
Amal has led due diligence, deal structuring and negotiations for more than 20 transactions, with a combined deal value of $500M.
“The treatment of pain continues to pose a great challenge as there is a high unmet need for safe and effective pain therapies.”
CHIEF EXECUTIVE OFFICER & DIRECTOR 1,3
Having first met him in university, Antibe’s founder, John Wallace, reconnected with Dan nearly 30 years later, seeking to tap his talent for leading senior teams in building best-in-class ventures.
JD Queen’s University, Canada
Dan’s leadership experience began with eight years as a military pilot, principally as an air rescue captain.
“We think we’ve solved one of the significant, long-standing medical problems of our time.”
FOUNDER, CHIEF SCIENTIFIC OFFICER & DIRECTOR
John is widely recognized as an expert in gastrointestinal inflammation and in the development of innovative anti-inflammatory medicines. In the mid-1990s, he co-founded NicOx and chaired its Scientific Advisory Board. (NicOx was the first company to achieve regulatory approval for drugs using gasotransmitters.)
PhD Medical Science University of Toronto, Canada
John received the Premier’s Summit Award in Innovation in 2009, financially the largest prize awarded to an individual scientist in Canada. He is also the recipient of the 2011 William Harvey Medal from the William Harvey Institute in London, UK. John was awarded the Heymans Foundation Medal in 2013—one of only twelve scientists so honored since the foundation was established nearly 50 years ago.
“Gastrointestinal damage from NSAIDs has been a clinically significant problem since first observed with aspirin, which was introduced more than 100 years ago.”
CEO MaRS Discovery District, Canada
Entrepreneurial Masters Program Massachusetts Institute of Technology, USA
Yung was recognized as one of Canada’s “Top 40 under 40” leaders earlier in his career and as chief executive of one of Canada’s “50 Best Managed Private Companies”.
“Antibe ranks amongst the most promising biotech companies that we work with.”
1. Audit Committee
2. Compensation Committee
3. Governance Committee